Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced that it has received funding from the Gates Foundation to support the advancement of the company’s lead mRNA-based product candidate, ETH47.
June 18, 2024
· 3 min read